Replies to post #102210 on Biotech Values

[DewDiligence]

IDIX Major Shareholders

[Updated for small true-up purchase by NVS on 8/23/10.]


The percentages in the table are based on 78.9.M diluted shares,
the count I use for valuation purposes (#msg-49785732); these
percentages differ from the ones reported in SEC filings.

 
                      Shares    Stake 
 Novartis           31,361,401  39.7% 
 T Rowe Price        8,101,442† 10.3% 
 JP Sommadossi (CEO) 4,026,004*  5.1% 
 BB/MPM Capital      3,321,534   4.2% 
 GlaxoSmithKline     2,474,527   3.1% 

†Based on Form 13G filed 5/10/10.
*Includes 1.8M vested and non-vested options.